Beacon Investment Advisory Services Inc. Cuts Position in Insulet Corporation $PODD

Beacon Investment Advisory Services Inc. decreased its holdings in Insulet Corporation (NASDAQ:PODD) by 11.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 71,950 shares of the medical instruments supplier’s stock after selling 9,390 shares during the quarter. Beacon Investment Advisory Services Inc. owned 0.10% of Insulet worth $20,451,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Winnow Wealth LLC acquired a new stake in Insulet in the 3rd quarter valued at $862,000. Machina Capital S.A.S. acquired a new position in Insulet during the third quarter worth $2,778,000. Jain Global LLC raised its position in Insulet by 148.2% during the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock worth $32,945,000 after acquiring an additional 63,719 shares during the period. Nordea Investment Management AB lifted its holdings in Insulet by 35.0% during the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after purchasing an additional 142,922 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in Insulet by 38.1% during the third quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock valued at $14,286,000 after purchasing an additional 12,754 shares in the last quarter.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. TD Cowen cut shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price for the company. in a research note on Monday, January 26th. Canaccord Genuity Group decreased their price target on shares of Insulet from $450.00 to $435.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. Barclays reiterated an “underweight” rating and issued a $286.00 price objective on shares of Insulet in a report on Thursday, February 19th. Stifel Nicolaus reduced their target price on Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a report on Wednesday, February 4th. Finally, UBS Group restated a “buy” rating on shares of Insulet in a research report on Thursday, December 18th. Twenty investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $354.24.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $208.22 on Monday. Insulet Corporation has a 52-week low of $208.14 and a 52-week high of $354.88. The stock has a market cap of $14.66 billion, a P/E ratio of 59.49, a PEG ratio of 1.25 and a beta of 1.42. The business has a fifty day moving average of $245.74 and a two-hundred day moving average of $288.32. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business had revenue of $783.80 million for the quarter, compared to analyst estimates of $768.31 million. During the same quarter in the previous year, the firm earned $1.15 EPS. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. On average, research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Michael R. Minogue bought 2,030 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were bought at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the acquisition, the director directly owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 0.39% of the stock is owned by company insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.